The Schwab U.S. Dividend Equity ETF (SCHD) has defied bearish macroeconomic conditions by delivering strong returns, largely due to its top holdings such as Abbott Laboratories (ABT), Merck (MRK), and Amgen (AMGN) which posted significant gains after major positive news. SCHD's focus on dividend growth and stable income makes holding the ETF beneficial despite market headwinds, as waiting for a deeper pullback risks missing valuable dividend payouts. This performance challenges previous expectations and highlights the importance of dividend-focused investing even in uncertain markets.
The Schwab US Dividend Equity ETF (SCHD) has increased its exposure to technology stocks, with Texas Instruments and Qualcomm becoming its largest holdings after the recent rebalance. This shift has raised the fund's weighted average look-through cas...
The Schwab U.S. Dividend Equity ETF (SCHD) faces challenges from rising interest rates due to its dividend focus, often seen as bond-like. However, its significant exposure to energy (14%) and financial sectors (10%) provides strong support, benefiti...
In 2026, the Schwab U.S. Dividend Equity ETF (SCHD) has outperformed the SPDR S&P 500 ETF (SPY) by nearly 10 percentage points year-to-date, with SCHD up 22.18% compared to SPY's 12.52%. SCHD's latest dividend payout also increased, reflecting its fo...
The Vanguard High Dividend Yield ETF (VYM) remains a 'hold' recommendation because it offers a consistent but average performance with a moderate dividend yield of 2.42%. While VYM provides strong sector and company diversification and a long dividen...
The Fidelity High Dividend ETF (FDVV) offers a competitive 2.98% dividend yield along with strong growth, value, and quality metrics. Despite some holdings in low-yield tech stocks, FDVV has shown resilience across different market conditions over it...
